PTHLH and cancer: Likewise, dasatinib, a selective SFK inhibitor, was shown to significantly reduce PTHrP-induced M-MDSC mobilization in vivo (Fig. 7c), supporting that SFK tyrosine kinase inhibitors could be repositioned to suppress MDSCs and to enhance cancer immunotherapy.